Cumberland Pharmaceuticals Inc. (CPIX)
- Previous Close
1.6350 - Open
1.7000 - Bid 1.1400 x 200
- Ask 2.1800 x 200
- Day's Range
1.7000 - 1.7000 - 52 Week Range
1.4300 - 2.3600 - Volume
99 - Avg. Volume
9,511 - Market Cap (intraday)
24.1M - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4400 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
www.cumberlandpharma.com91
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CPIX
Performance Overview: CPIX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CPIX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CPIX
Valuation Measures
Market Cap
24.10M
Enterprise Value
24.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.61
Price/Book (mrq)
0.81
Enterprise Value/Revenue
0.61
Enterprise Value/EBITDA
9.74
Financial Highlights
Profitability and Income Statement
Profit Margin
-15.88%
Return on Assets (ttm)
-4.44%
Return on Equity (ttm)
-19.41%
Revenue (ttm)
39.55M
Net Income Avi to Common (ttm)
-6.28M
Diluted EPS (ttm)
-0.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
18.32M
Total Debt/Equity (mrq)
62.98%
Levered Free Cash Flow (ttm)
9.33M